the aid library

LIST OPTIONS

Filter

5374

National Guidelines and Operational Manual for Programmatic Management of Drug Resistant TB (PMDT), 2nd ed.

Government of the People’s Republic of Bangladesh, Directorate General of Health Services (2013) C1

Specific measures are being taken within the National Tuberculosis Control Programme (NTP) to address the MDR TB problem through appropriate management of patients and strategies to prevent the propagation and dissemination of MDR TB.
The term "Programmatic Management of Drug Resistant TB" (PMD... more

Download (508)

View PDF (540)

GUIDELINES FOR GOOD CLINICAL LABORATORY PRACTICES (GCLP)

Indian Council of Medical Research (ICMR) (2008) C1

Guidelines for Good Clinical Laboratory Practices (GCLP) outlines the principles and procedures to be followed by medical laboratories involved in clinical research and/or patient care so as to provide quality data which can be used for health research and patient treatment. As the use of laboratory... more

Download (421)

View PDF (451)

A8 e-Therapy using computer and mobile technologies in treatment

Karolina Stasiak & Sally Merry IACAPAP (2015) C2

This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o... more

Download (576)

View PDF (707)

Second WHO Model List of Essential In Vitro Diagnostics

World Health Organization WHO (2019) C_WHO

The updated List of Essential Diagnostics contains 46 general tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions, and 69 tests intended for the detection, diagnosis and monitoring of specific diseases. The List is divid... more

PC Senegal Community Health Manual - 2014 Edition

Berlin, E.; C. Cravero, S. Danner et. al. Peace Corps (2014) C2

Public Health is the science field dedicated to promoting health and well-being, and preventing disease within the human population to ultimately increase the quality of our livelihood and life span. Public Health does not focus on individual patients or diseases, but rather a given population and ... more

Download (166)

View PDF (193)

COVID-19 and Violence Against Health-Care – Safer COVID-19 Response: Checklist for Health-Care Services

International Committee of the Red Cross ICRC (2020) C1

The Safer COVID-19 Response checklist has been produced for managers of health-care services, individual practitioners and health policymakers worried about the impact of violence against health-care workers, facilities and patients during the COVID-19 response. It provides a practical, actionable s... more

Corticosteroids for COVID-19

World Health Organization WHO (2020) C_WHO

WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19. We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients ... more

Africa CDC Consortium for COVID-19 Vaccine Clinical Trials (CONCVACT)

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C1

August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac... more

Download (145)

View PDF (162)

Use of chest imaging in COVID-19 (Arab Version)
recommended

World Health Organization WHO (2020) C_WHO

This rapid advice guide examines the evidence and makes recommendations for the use of chest imaging in acute care of adult patients with suspected, probable or confirmed COVID-19. Imaging modalities considered are radiography, computed tomography and ultrasound. This guide addresses the care pathwa... more

Download (244)

View PDF (310)

Review on palliative care with focus on 18 high tuberculosis priority countries

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Tuberculosis (‎TB)‎ is, and should be, a curable disease; however, each year significant numbers of patients acquire or develop drug-resistant TB, which has a much lower cure rate. Patients with drug-resistant TB have a high prevalence of symptoms; hence, staff caring for these patients should h... more

Pulse Oximetry Training Manual

World Health Organization WHO (2011) C_WHO

Welcome to the World Health Organization pulse oximeter training manual. In many countries pulse oximetry is mandatory for monitoring patients during anaesthesia. Although pulse oximetry is a simple and reliable technology that can detect low levels of oxygen in the blood, it is only effective if t... more

Hypertension Control Change Package

Centers for Disease Control and Prevention (CDC) (2020) C_CDC

second edition Included more self-measured blood pressure (SMBP)-focused content with tools and resources. Showcased more tools to find patients with potentially undiagnosed HTN. Added new strategies that focus on chronic kidney disease testing and identification.

Guidelines for the production of extemporaenous formulations and hospital based sterile preparations

Tanzania Food and Drugs Authority TFDA (2017) CC

In order to streamline and effectively control compounding of medicinal products in hospitals and pharmacies, these Guidelines for Production of Extemporaneous and Hospital Based Sterile Preparations has been crafted. The purpose of these guidelines therefore is to assist pharmacists in ... more

Download (114)

View PDF (156)

Drug Regulation in Kenya

LEAP (2021) CC

Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.

Download (225)

View PDF (260)

Psychosocial counselling and treatment adherence support for people affected by tuberculosis

The Union (2021) C1

The guide is suitable and can be used for the following audiences: 1. nurses and other trained healthcare workers who can use this manual as a self-study tool and then incorporate its guidance into their practice; 2. governmental and non-governmental employers of lay and professional TB treatment ... more

Download (130)

View PDF (179)

Perceptions and experiences of nurses about the mobile clinic work environment

Stemmet, C.L. (2016) C1

Thesis presented in partial fulfilment of the requirements for the degree of Master of Nursing Science in the Faculty of Health Sciences at Stellenbosch University. The mobile clinic health care services fulfil an essential role in delivering primary health care to the dwellers in the rural commun... more

External Link

Chagas Clinical Research Platform Newsletter

Drugs for Neglected Diseases Initiative DNDi Latin America (2022) CC

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f... more

External Link

Rabies vaccines and immunoglobulins: WHO position

World Health Organization WHO (2017) C_WHO

The new WHO recommendations for rabies immunization supersede the 2010 WHO position on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for rabies. These updated recommendations are based on new evidence and directed by public health needs that are cost-, dose- and time-sparing... more

Download (133)

View PDF (126)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Use of chest imaging in COVID-19 (Arab Version) recommended

Use of chest imaging in COVID-19 (Arab Version)
recommended